Health Canada approves Pluvicto for prostate cancer treatment

By staff writers

September 8, 2022 -- Health Canada has approved lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) radioligand therapy (Pluvicto, Novartis) for the treatment of patients with metastatic prostate cancer.

The radiopharmaceutical drug is indicated for adult patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other anticancer therapies, such as androgen receptor therapy or taxane-based chemotherapy.

Prostate cancer is the most diagnosed cancer among Canadian men and is the third leading cause of cancer-related death in men in Canada.

Pluvicto was approved by the U.S. Food and Drug Administration in March.

Copyright © 2022
Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking